almagate has been researched along with Stroke in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| AbouChehade, JE; Bakri, SJ; Dalvin, LA; Damento, GM; Garcia, M; Hodge, DO; Iezzi, R; Meissner, I; Shah, SM; Starr, MR | 1 |
| AbouChehade, JE; Bakri, SJ; Dalvin, LA; Damento, GM; Garcia, MD; Hodge, DO; Iezzi, R; Meissner, I; Shah, SM; Starr, MR | 1 |
| Kanwar, JR; Kanwar, R; Sriramoju, B; Veedu, RN | 1 |
| Matthé, E; Sandner, D | 1 |
| Joussen, AM; Wong, D | 1 |
1 review(s) available for almagate and Stroke
| Article | Year |
|---|---|
Aptamer-targeted oligonucleotide theranostics: a smarter approach for brain delivery and the treatment of neurological diseases.
Topics: Alzheimer Disease; Aptamers, Nucleotide; Aptamers, Peptide; Blood-Brain Barrier; Brain Neoplasms; Drug Delivery Systems; Humans; Macular Degeneration; Molecular Targeted Therapy; Multiple Sclerosis; Myasthenia Gravis; Parkinson Disease; SELEX Aptamer Technique; Stroke; Theranostic Nanomedicine | 2015 |
4 other study(ies) available for almagate and Stroke
| Article | Year |
|---|---|
Association of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy With Risk of Stroke, Myocardial Infarction, and Death in Patients With Exudative Age-Related Macular Degeneration.
Topics: Aged; Aptamers, Nucleotide; Cause of Death; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Intravitreal Injections; Macula Lutea; Male; Minnesota; Myocardial Infarction; Prognosis; Retrospective Studies; Risk Assessment; Risk Factors; Stroke; Survival Rate; Time Factors; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Wet Macular Degeneration | 2019 |
Classification of Strokes in Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor.
Topics: Aged; Angiogenesis Inhibitors; Aptamers, Nucleotide; Bevacizumab; Dihydropyridines; Female; Follow-Up Studies; Humans; Intravitreal Injections; Male; Middle Aged; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retinal Diseases; Retrospective Studies; Stroke; Vascular Endothelial Growth Factor A | 2019 |
[Monotherapy of exudative age-related macular degeneration with ranibizumab in patients at cardiovascular risk. Advantages of ranibizumab compared to a combination with pegaptanib].
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Coronary Artery Bypass; Coronary Disease; Drug Therapy, Combination; Female; Humans; Intravitreal Injections; Male; Myocardial Infarction; Ranibizumab; Retrospective Studies; Risk Factors; Stents; Stroke; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration | 2011 |
The safety of using anti-VEGF: Is there strength in numbers? Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthal
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Cause of Death; Hemorrhage; Humans; Macular Degeneration; Myocardial Infarction; Photochemotherapy; Ranibizumab; Risk Factors; Stroke; Vascular Endothelial Growth Factor A | 2011 |